



**AMANDA GALLO**  
**18-Aug-1967**      **Female**

PO BOX 710  
ATHERTON QLD 4883

P: 1300 688 522  
E: info@nutripath.com.au

**-.VERA DAHLSTROM**  
**RESTORING VITALITY NATUROPATHIC**  
**CLINIC**  
**2 TOROKINA STREET**

LAB ID :                    4126637  
UR NO. :                   6392587  
Collection Date :       28-Jul-2025  
Received Date:          30-Jul-2025



4126637

Clinical Notes: MHT gel

HAEMATOLOGY			
BLOOD - CITRATE	Result	Range	Units
<b>FIBRINOGEN</b>	<b>2.8</b>	2.0 - 4.5	g/L
<b>HAEMATOLOGY COMMENTS</b>	Fibrinogen test performed by accredited laboratory NATA: 2133		



BIOCHEMISTRY			
BLOOD - SERUM	Result	Range	Units




4126637

Clinical Notes: MHT gel


**LIPIDS**

Cholesterol	4.7	0.0 - 5.5	mmol/L
Triglycerides	0.7	0.0 - 2.0	mmol/L



**LIPID STUDIES**


HDL(Protective)	1.8	1.0 - 2.2	mmol/L
Non-HDL Cholesterol	2.98	< 4.0	mmol/L
LDL(Atherogenic)	2.7	0.0 - 3.4	mmol/L
Cholesterol/HDL Ratio	2.7		
LDL/HDL RATIO (Risk Factor)	1.5	0.0 - 3.2	
Trig/HDL Ratio	0.4 *L	0.5 - 1.7	RATIO



Lipoprotein (a)	8.0	0.0 - 75.0	nmol/L
-----------------	-----	------------	--------


**APOLIPOPROTEIN PROFILE**

Apolipoprotein B	0.67	0.60 - 1.30	g/L
Apolipoprotein A-1	1.55	1.10 - 2.05	g/L
RATIO (APO B / APO A-1)	0.43	0.35 - 1.15	
High Sens CRP	0.26	0.00 - 5.00	mg/L




**LIPOSCREEN LDL Subfractions2**

Very Low Density Lipoprotein (VLDL)	0.6	0.1 - 0.6	mmol/L
Intermediate Density Lipoprotein (IDL-1)	0.5	0.1 - 0.6	mmol/L
Intermediate Density Lipoprotein (IDL-2)	0.1	0.1 - 0.4	mmol/L
Intermediate Density Lipoprotein (IDL-3)	0.3	0.1 - 0.6	mmol/L
Low Density Lipoprotein (LDL-1)	1.13	0.10 - 1.50	mmol/L
Low Density Lipoprotein (LDL-2)	0.41	0.10 - 0.80	mmol/L
Low Density Lipoprotein (LDL-3)	0.00	0.00 - 0.20	mmol/L
Low Density Lipoprotein (LDL-4)	0.00	0.00 - 0.01	mmol/L
Low Density Lipoprotein (LDL-5)	0.00	0.00 - 0.01	mmol/L
Low Density Lipoprotein (LDL-6)	0.00	0.00 - 0.01	mmol/L
Low Density Lipoprotein (LDL-7)	0.00	0.00 - 0.01	mmol/L
Mean Particle Size	273.0	> 268.0	Angstrom
LDL Phenotype Pattern			



Type A- Normal



Reference ranges derived from 125 serum samples that met the NCEP ATP III guidelines for desirable lipid status.  
\*LDL-C is comprised of the sum of cholesterol in LDL bands C through A as well as all the subfractions.

(\*) Result outside normal reference range

(L) Result is below lower limit of reference range

**-.VERA DAHLSTROM**  
**RESTORING VITALITY NATUROPATHIC**  
**CLINIC**  
**2 TOROKINA STREET**

LAB ID : 4126637  
UR NO. : 6392587  
Collection Date : 28-Jul-2025  
Received Date: 30-Jul-2025



4126637

Clinical Notes: MHT gel

## LIPOSCREEN Comments

### RESULT INTERPRETATION

The Liposcreen LDL Subtractions test provides a superior indicator for Coronary Artery Disease (CAD) risk than other conventionally available lipid profiles. Many individuals with normal LDL and HDL cholesterol levels remain at risk from CAD as these conventional tests do not convey the detail of the CAD risk. Liposcreen additionally quantifies the different subfractions.

Liposcreen clearly identifies a patient's LDL phenotype profile;

*This patient has a profile indicative of Type A, which is deemed normal.*

*Of note is the elevated VLDL band, which when elevated are also deemed highly atherogenic.*

### Lipoprotein Pattern Characteristics:

(Patient may have some or all of these present)

Type A	Deemed a normal profile. Predominance of large/buoyant (less atherogenic) LDL subclasses (LDL 1 and 2). Mean Particle Size of > 263 Angstrom (A). Elevated Cholesterol, Normal Triglycerides, Elevated Apo B
Type B	Deemed an ABNORMAL profile. Predominance of small/dense (more atherogenic) LDL subclasses (LDL3, 4, 5, 6, 7). Mean Particle Size of < 258 Angstrom (A). Raised Cholesterol, Raised Triglycerides, Raised VLDL, Low HDLC This profile is the designated atherogenic lipoprotein phenotype, consistent with an increased risk of CAD. It is also It is also characteristically prevalent in insulin-resistant states such as Metabolic Syndrome and Type 2 Diabetes mellitus.

Follow up Liposcreen testing, for this patient, is recommended in 12 months.

## Lipid Profile Comment

Target Levels for the general population and the National Vascular Disease Prevention Alliance (NVDPA) treatment target levels for high-risk people (known coronary heart and other arterial diseases, diabetes, chronic renal failure, Aboriginal and Torres Strait Islander peoples and familial hyperlipidaemic conditions) are:

	Tot. Cholesterol	LDL-Cholesterol	HDL-Cholesterol
General population:	<5.5 mmol/L	<3.0 mmol/L	M: >=1.0, F: >=1.0 mmol/L
At risk individuals:	<4.0 mmol/L	<2.5 mmol/L	

At risk:

Fasting Triglycerides:	<2.0 mmol/L
Non-HDL Cholesterol:	<3.3 mmol/L

National guidelines generally specify specific targets, refer to [www.cvdcheck.org.au](http://www.cvdcheck.org.au)



AMANDA GALLO  
18-Aug-1967 Female

PO BOX 710  
ATHERTON QLD 4883

P: 1300 688 522  
E: info@nutripath.com.au

-VERA DAHLSTROM  
RESTORING VITALITY NATUROPATHIC  
CLINIC  
2 TOROKINA STREET

LAB ID : 4126637  
UR NO. : 6392587  
Collection Date : 28-Jul-2025  
Received Date: 30-Jul-2025



4126637

Clinical Notes: MHT gel

BIOCHEMISTRY				
BLOOD - SERUM	Result	Range	Units	
GLUCOSE (FASTING)	5.1	3.0 - 5.4	mmol/L	
BLOOD - PLASMA				
Homocysteine	10.2	5.0 - 15.0	umol/L	

Tests ordered: FIB,FATS,FGLU,LIP,HOMO,Lipo (a),APOS,HCRP,CFee,LIPOSCRN2,BioPEI,GOG137

(\*) Result outside normal reference range

(L) Result is below lower limit of reference range